András Szollár1, Mihály Újhelyi2, Csaba Polgár3, Edit Oláh4, Dávid Pukancsik1, Gábor Rubovszky5, Nóra Udvarhelyi6, Tibor Kovács7, Ákos Sávolt1, István Kenessey8, Zoltán Mátrai1. 1. National Institute of Oncology, Department of Breast and Sarcoma Surgery, Ráth György Str. 7-9. 1122, Budapest, Hungary. 2. National Institute of Oncology, Department of Breast and Sarcoma Surgery, Ráth György Str. 7-9. 1122, Budapest, Hungary. Electronic address: ujhelyi@oncol.hu. 3. National Institute of Oncology, Centre of Radiotherapy, Ráth György Str. 7-9. 1122, Budapest, Hungary; Semmelweis University, Department of Oncology, Ráth György Str. 7-9. 1122, Budapest, Hungary. 4. National Institute of Oncology, Department of Molecular Genetics, Ráth György Str. 7-9. 1122, Budapest, Hungary. 5. National Institute of Oncology, Department of Oncological Internal Medicine and Clinical Pharmacology, Ráth György Str. 7-9. 1122, Budapest, Hungary. 6. National Institute of Oncology, Centre of Pathology, Ráth György Str. 7-9. 1122 Budapest, Hungary. 7. Guy's Hospital, Breast Unit, London, Great Maze Pond, London, SE1 9RT, United Kingdom. 8. National Institute of Oncology, National Cancer Registry, Ráth György Str. 7-9. 1122, Budapest, Hungary; Semmelweis University, Second Department of Pathology, Üllői Str. 93. 1091, Budapest, Hungary.
Abstract
BACKGROUND: Breast cancer diagnosed in very young women (VYWBC; ≤35 years) and young women (YWBC; 36-45 years) tends to be heterogeneous. The current study aimed to compare the clinicopathological characteristics and long-term clinical outcomes between YWBC and VYWBC subgroups. PATIENTS AND METHODS: The institutional prospectively led database was retrospectively analysed from 2000 to 2014 at the National Institute of Oncology, Hungary. A total of 297 patients were assigned to the VYWBC group, and 301 patients were assigned to the YWBC group. RESULTS: The median follow-up period was 69 months for the VYWBC group and 79 months for the YWBC group. Significant differences were observed based on breast cancer subtype. The proportion of Triple-negative and ER-negative patients was higher in the VYWBC group than in the YWBC group (P = 0.00008). The incidence of distant metastasis was significantly higher in the VYWBC group (P = 0.01). Significant differences in the frequency of chemotherapy (P = 0.049) and endocrine therapy (P = 0.037) were observed between the two groups. The YWBC group exhibited significantly better overall survival (OS) and disease-free survival (DFS) rates than did the VYWBC group (P = 0.00005 and P = 0.00004, respectively). CONCLUSION: Breast cancers in VYWBC are biologically different from those in YWBC and tend to be more aggressive. Younger age was associated with worse OS and DFS. Young women with breast cancer should be subgrouped into VYWBC and YWBC populations, and these subgroups should be targeted by specialized clinical trials and further investigations.
BACKGROUND:Breast cancer diagnosed in very young women (VYWBC; ≤35 years) and young women (YWBC; 36-45 years) tends to be heterogeneous. The current study aimed to compare the clinicopathological characteristics and long-term clinical outcomes between YWBC and VYWBC subgroups. PATIENTS AND METHODS: The institutional prospectively led database was retrospectively analysed from 2000 to 2014 at the National Institute of Oncology, Hungary. A total of 297 patients were assigned to the VYWBC group, and 301 patients were assigned to the YWBC group. RESULTS: The median follow-up period was 69 months for the VYWBC group and 79 months for the YWBC group. Significant differences were observed based on breast cancer subtype. The proportion of Triple-negative and ER-negative patients was higher in the VYWBC group than in the YWBC group (P = 0.00008). The incidence of distant metastasis was significantly higher in the VYWBC group (P = 0.01). Significant differences in the frequency of chemotherapy (P = 0.049) and endocrine therapy (P = 0.037) were observed between the two groups. The YWBC group exhibited significantly better overall survival (OS) and disease-free survival (DFS) rates than did the VYWBC group (P = 0.00005 and P = 0.00004, respectively). CONCLUSION:Breast cancers in VYWBC are biologically different from those in YWBC and tend to be more aggressive. Younger age was associated with worse OS and DFS. Young women with breast cancer should be subgrouped into VYWBC and YWBC populations, and these subgroups should be targeted by specialized clinical trials and further investigations.
Authors: Sofia I Vuorinen; Rachel K Okolicsanyi; Martina Gyimesi; Jacob Meyjes-Brown; Deepa Saini; Son H Pham; Lyn R Griffiths; Larisa M Haupt Journal: J Cancer Res Clin Oncol Date: 2022-09-24 Impact factor: 4.322
Authors: Zoltán Mátrai; Péter Kelemen; Csaba Kósa; Róbert Maráz; Attila Paszt; Gábor Pavlovics; Ákos Sávolt; Zsolt Simonka; Dezső Tóth; Miklós Kásler; Andrey Kaprin; Petr Krivorotko; Ferenc Vicko; Piotr Pluta; Agnieszka Kolacinska-Wow; Dawid Murawa; Jerzy Jankau; Slawomir Ciesla; Daniel Dyttert; Martin Sabol; Andrii Zhygulin; Artur Avetisyan; Alexander Bessonov; György Lázár Journal: Pathol Oncol Res Date: 2022-06-15 Impact factor: 2.874
Authors: Sujha Subramanian; Florence K L Tangka; Patrick Edwards; Madeleine Jones; Tim Flanigan; Jenya Kaganova; Kevin Smith; Cheryll C Thomas; Nikki A Hawkins; Juan L Rodriguez; Gery P Guy; Temeika Fairley Journal: Cancer Causes Control Date: 2020-09-08 Impact factor: 2.506